Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

NCT ID: NCT05846750

Last Updated: 2023-07-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 59 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-01
• Study Completion Date: 2028-05-31

Brief Summary

This is a prospective, multicenter clinical study that will enroll 59 patients with relapsed and refractory (R/R) MZL. The study is designed to evaluate the efficacy and safety of the combination of obinutuzumab and lenalidomide in the treatment of relapsed and refractory marginal zone lymphoma (MZL).

Detailed Description

Marginal zone lymphoma (MZL) is incurable, and the vast majority of patients with MZL eventually face disease relapse or progression.

There is no standard second-line treatment for relapsed/refractory MZL, and the synergistic effect of obinutuzumab and lenalidomide has been demonstrated in other indolent lymphomas.

The aim of this trial is to investigate the efficacy and safety of the combination of obinutuzumab (GA101) and lenalidomide in the treatment of R/R marginal zone lymphoma in order to find a safe and effective option for this type of disease.

Conditions

Marginal Zone Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Obinutuzumab and lenalidomide

Patients will be treated with obinutuzumab and lenalidomide for 6 cycles as induction, and the patients who achieve at least a partial response after 6 cycles of induction therapy will be eligible to enter the maintenance phase for 2 years

Group Type: EXPERIMENTAL

Obinutuzumab

Intervention Type: DRUG

Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；

Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression

lenalidomide

Intervention Type: DRUG

Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；

Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression

Interventions

Obinutuzumab

Induction (6 cycles, every 28 days/cycle): 1000 mg each time, administered on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6 ( 8 total infusions)；

Maintenance(12 cycles, every 2 months/cycle): 12 infusions of 1000 mg every 2 months for 2 years or until disease progression

Intervention Type: DRUG

lenalidomide

Induction( 6 cycles, every 28 days/cycle): 20 mg/day, oral, Dosing on Days 2-22, every 28 days/cycle of Cycles 1-6；

Maintenance(12 cycles, every 28 days/cycle):10 mg on Days 2-22 of each 28-day cycle, 12 cycles for 1 year or until disease progression

Intervention Type: DRUG

Other Intervention Names

GA101

Eligibility Criteria

Inclusion Criteria

1. Signed Informed Consent Form

2. Age ≥18 years

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

4. Histologically confirmed MZL. have a definite diagnosis of MZL

5. Prior treatment with at least one line of systemic lymphoma including prior immunotherapy or chemoimmunotherapy

6. At least one bi-dimensionally measurable nodal lesion (> 1.5 cm in greatest diameter on CT scan or MRI) OR at least one bi-dimensionally measurable extranodal lesion (> 1.0 cm in greatest diameter on CT scan or MRI)

7. Need for systemic therapy as assessed by the investigator

8. Life expectancy ≥ 3 months

9. Adequate blood function (except for abnormalities considered by the investigator to be due to the underlying disease of lymphoma), defined as follows:

Hemoglobin ≥ 7 g/dL; Absolute neutrophil count ≥ 1.0 × 109/L; Platelet count ≥ 50 x 109/L

10. Normal laboratory values:

Creatinine clearance ≥ 30 mL/min; Glutathione transaminase(AST) or glutathione aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ≤ 2 × ULN (≤ 3 × ULN in patients with Gilbert's syndrome)

11. For men who are not surgically sterile: Agree to use barrier contraception during treatment and for at least 3 months after the last dose of obinutuzumab or lenalidomide or as required by institutional guidelines, whichever is longer. In addition, male patients must agree to have their partner use an alternative method of contraception (e.g., oral contraceptive, intrauterine device, barrier method, or spermicide)

12. For women who are not surgically sterile: use two appropriate methods of contraception, such as oral contraceptives, intrauterine device, or barrier methods, in combination with spermicide for at least 28 days prior to agreeing to start of study medication, during treatment and for at least 12 months after the last dose of either obinutuzumab or lenalidomide, or as required by institutional guidelines, whichever is longer -

Exclusion Criteria

1. Patients who are refractory or resistant to lenalidomide or obinutuzumab, refractory is defined as no response (PR or CR) after the start of treatment, or relapse within 6 months (≤ 2 cycles of prior lenalidomide or obinutuzumab and no exclusion of treatment change for non-refractory reasons)

2. History of serious allergic or anaphylactic reactions to monoclonal antibody therapy

3. Known hypersensitivity to any of the study drugs

4. Known sensitivity to murine products

5. Previous ≥ Grade 3 allergic reactions/Hypersensitivity to thalidomide

6. History of erythema multiforme, Grade 3 rash, or blisters following prior immunomodulatory derivative therapy

7. Histologically transformed, highly malignant or diffuse large B-cell lymphoma

8. Central nervous system or meningeal involvement by lymphoma

9. Contraindications for the investigational medical product included in the study treatment regimen

10. Positive test for chronic hepatitis B infection (defined as positive HBsAg serology)

11. Hepatitis C positive (hepatitis C virus antibody serology)

12. HIV or Human T-Lymphocytic Leukemia Virus 1 (HTLV1) positive

13. Evidence of any serious, uncontrolled co-morbidities that affect compliance with the protocol or interpretation of results, including but not limited to significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmias, or unstable angina), or significant pulmonary disease (including history of obstructive pulmonary disease or bronchospasm)

14. Infection caused by known active bacteria, viruses, fungi, or other microorganisms (other than fungal infection of the nail bed), or any major infection requiring intravenous antibiotics or hospitalization (completion of the entire course of antibiotics, except for neoplastic fever) within 4 weeks prior to enrollment

15. Prior malignancy other than lymphoma, unless the subject has a disease-free survival of ≥ 5 years

16. Pregnant or lactating women.

17. Have ≥ Grade 2 neuropathy

18. Participation in another clinical trial using a pharmacological intervention during the trial or within 28 days prior to Cycle 1

19. Corticosteroids within 4 weeks of enrollment, unless administered at a dose equivalent to ≤ 30 mg/day prednisone (within 4 weeks)

20. Past history of progressive multifocal leukoencephalopathy (PML)

21. Live vaccines within 28 days of treatment start

22. History of solid organ transplantation

23. Presence of any serious illness or abnormality in the clinical laboratory test results that, in the opinion of the investigator, would make the patient unable to safely participate and complete this study, or affect protocol compliance or interpretation of results

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Shuhua Yi, Dr

Role: PRINCIPAL_INVESTIGATOR

Institute of Hematology & Blood Diseases Hospital, Chinese

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tian, China

Site Status: RECRUITING

Countries

China

Central Contacts

shuhua Yi, Dr

Role: CONTACT

yishuhua@ihcams.ac.cn

86-22-23909106

Lugui Qiu, Dr

Role: CONTACT

qiulg@ihcams.ac.cn

86-22-23909172

Facility Contacts

Rui Lyu

Role: primary

86-22-23909106

Other Identifiers

BDHMZL2023

Identifier Type: -

Identifier Source: org_study_id